CoChat

Platelet-rich therapies for musculoskeletal soft tissue injuries

Moraes, Vinícius Y, Lenza, Mário, Tamaoki, Marcel Jun, Faloppa, Flávio, Belloti, João Carlos · 2013 · Cochrane Database of Systematic Reviews
Cited by 156

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Platelet-rich therapies are being used increasingly in the treatment of musculoskeletal soft tissue injuries such as ligament, muscle and tendon tears and tendinopathies. These therapies can be used as the principal treatment or as an augmentation procedure (application after surgical repair or reconstruction). Platelet-rich therapies are produced by centrifuging a quantity of the patient's own blood and extracting the active, platelet-rich, fraction. The platelet-rich fraction is applied to the injured tissue; for example, by injection. Platelets have the ability to produce several growth factors, so these therapies should enhance tissue healing. There is a need to assess whether this translates into clinical benefit. OBJECTIVES: To assess the effects (benefits and harms) of platelet-rich therapies for treating musculoskeletal soft tissue injuries. SEARCH METHODS: We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (25 March 2013), the Cochrane Central Register of Controlled Trials (CENTRAL 2013 Issue 2), MEDLINE (1946 to March 2013), EMBASE (1980 to 2013 Week 12) and LILACS (1982 to March 2012). We also searched trial registers (to Week 2 2013) and conference abstracts (2005 to March 2012). No language or publication restrictions were applied. SELECTION CRITERIA: We included randomised and quasi-randomised controlled trials that compared platelet-rich therapy with either placebo, autologous whole blood, dry needling or no platelet-rich therapy for people with acute or chronic musculoskeletal soft tissue injuries. Primary outcomes were functional status, pain and adverse effects. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data and assessed each study's risk of bias. Disagreement was resolved by discussion or by arbitration by a third author. We contacted trial authors for clarification of methods or missing data. Treatment effects were assessed using risk ratios for dichotomous data and mean differences (MD) or standardised mean differences (SMD) for continuous data, together with 95% confidence intervals. Where appropriate, data were pooled using the fixed-effect model for RR and MD, and the random-effects model for SMD. The quality of the evidence for each outcome was assessed using GRADE criteria. MAIN RESULTS: We included data from 19 small single centre trials (17 randomised and two quasi-randomised; 1088 participants) that compared platelet-rich therapy with placebo, autologous whole blood, dry needling or no platelet-rich therapy. These trials covered eight clinical conditions: rotator cuff tears (arthroscopic repair) (six trials); shoulder impingement syndrome surgery (one trial); elbow epicondylitis (three trials); anterior cruciate ligament (ACL) reconstruction (four trials), ACL reconstruction (donor graft site application) (two trials), patellar tendinopathy (one trial), Achilles tendinopathy (one trial) and acute Achilles rupture surgical repair (one trial). We also grouped trials into 'tendinopathies' where platelet-rich therapy (PRT) injections were the main treatment (five trials), and surgical augmentation procedures where PRT was applied during surgery (14 trials). Trial participants were mainly male, except in trials including rotator cuff tears, and elbow and Achilles tendinopathies.Three trials were judged as being at low risk of bias; the other 16 were at high or unclear risk of bias relating to selection, detection, attrition or selective reporting, or combinations of these. The methods of preparing platelet-rich plasma (PRP) varied and lacked standardisation and quantification of the PRP applied to the patient.We were able to pool data for our primary outcomes (function, pain, adverse events) for a maximum of 11 trials and 45% of participants. The evidence for all primary outcomes was judged as being of very low quality.Data assessing function in the short term (up to three months) were pooled from five trials that assessed PRT in three clinical conditions and used four different measures. These showed no significant difference between PRT and control (SMD 0.24; 95% confidence interval (CI) -0.07 to 0.56; P value 0.13; I² = 35%; 273 participants; positive values favour PRT). Medium-term function data (at six months) were pooled from six trials that assessed PRT in five clinical conditions and used six different measures. These also showed no difference between groups (SMD 0.06; 95% CI -0.39 to 0.51; P value 0.79; I² = 64%; 262 participants). Long-term function data (at one year) were pooled from 10 trials that assessed PRT in five clinical conditions and used six different measures. These also showed no difference between groups (SMD 0.25, 95% CI -0.07 to 0.57; P value 0.12; I² = 66%; 484 participants). Although the 95% confidence intervals indicate the possibility of a slightly poorer outcome in the PRT group up to a moderate difference in favour of PRT at short- and long-term follow-up, these do not translate

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd010071.pub2

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 56

  1. Almeida, 2013, Platelet-rich plasma in the regeneration of the patellar ligament after harvesting its central third: a prospective randomised study [Efeito do plasma rico em plaquetas na regeneração do terço central do ligamento da patela: estudo prospectivo randomizado
  2. Almeida, 2012, Patellar tendon healing with platelet-rich plasma, American Journal of Sports Medicine, 40, 1283, 10.1177/0363546512441344 · DOI
  3. Antuña, 2013, Platelet-rich fibrin in arthroscopic repair of massive rotator cuff tears: A prospective randomized pilot clinical trial, Acta Orthopaedica Belgica, 79, 25
  4. Castricini, 2011, Platelet-rich plasma augmentation for arthroscopic rotator cuff repair: a randomized controlled trial, American Journal of Sports Medicine, 39, 258, 10.1177/0363546510390780 · DOI · Paper page
  5. Cervellin, 2012, Autologous platelet-rich plasma gel to reduce donor-site morbidity after patellar tendon graft harvesting for anterior cruciate ligamente reconstruction: a randomized, controlled clinical study, Knee Surgery, Sports Traumatology, Arthroscopy, 20, 114, 10.1007/s00167-011-1570-5 · DOI · Paper page
  6. Creaney, 2011, Growth factor-based therapies provide additional benefit beyond physical therapy in resistant elbow tendinopathy: a prospective, single-blind, randomised trial of autologous blood injections versus platelet-rich plasma injections, British Journal of Sports Medicine, 45, 966, 10.1136/bjsm.2010.082503 · DOI · Paper page
  7. Jonge, 2011, One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy, American Journal of Sports Medicine, 39, 1623, 10.1177/0363546511404877 · DOI · Paper page
  8. Vos, 2011, No effects of PRP on ultrasonographic tendon structure and neovascularization in chronic midportion Achilles tendinopathy, British Journal of Sports Medicine, 45, 387, 10.1136/bjsm.2010.076398 · DOI · Paper page
  9. Vos, 2010, Platelet-rich plasma injection for chronic Achilles tendinopathy, JAMA, 303, 144, 10.1001/jama.2009.1986 · DOI · Paper page
  10. Everts, 2008, Exogenous application of platelet-leukocyte gel during open subacromial decompression contributes to improved patient outcome, European Surgical Research, 40, 203, 10.1159/000110862 · DOI · Paper page
  11. Gumina, 2012, Use of platelet-leukocyte membrane in arthroscopic repair of large rotator cuff tears, Journal of Bone and Joint Surgery - American Volume, 94, 1345, 10.2106/JBJS.K.00394 · DOI · Paper page
  12. Krogh, 2013, Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline: a randomized, double-blind, placebo-controlled trial, American Journal of Sports Medicine, 41, 625, 10.1177/0363546512472975 · DOI · Paper page
  13. Orrego, 2008, Effects of platelet concentrate and a bone plug on the healing of hamstring tendons in a bone tunnel, Arthroscopy, 24, 1373, 10.1016/j.arthro.2008.07.016 · DOI · Paper page
  14. Randelli, 2011, Platelet rich plasma in arthroscopic rotator cuff repair: a prospective RCT study, 2-year follow-up, Journal of Shoulder and Elbow Surgery, 20, 518, 10.1016/j.jse.2011.02.008 · DOI · Paper page
  15. Rodeo, 2012, The effect of platelet-rich fibrin matrix on rotator cuff tendon healing: a prospective, randomized clinical study, American Journal of Sports Medicine, 40, 1234, 10.1177/0363546512442924 · DOI · Paper page
  16. Schepull, 2011, Autologous platelet have no effect on the healing of human achilles tendon ruptures: a randomized single-blind study, American Journal of Sports Medicine, 39, 38, 10.1177/0363546510383515 · DOI · Paper page
  17. Vadalà, 2013, Platelet-rich plasma: does it help reduce tunnel widening after ACL reconstruction?, Knee Surgery Sports Traumatology Arthroscopy, 21, 824, 10.1007/s00167-012-1980-z · DOI
  18. Valentí Nín, 2009, Has platelet-rich plasma any role in anterior cruciate ligament allograft healing?, Arthroscopy, 25, 1206, 10.1016/j.arthro.2009.06.002 · DOI · Paper page
  19. Vogrin, 2010, The effect of platelet-derived growth factors on knee stability after anterior cruciate ligament reconstruction: a prospective randomized clinical study, Wiener Klinische Wochenschrift, 122, 91, 10.1007/s00508-010-1340-2 · DOI
  20. Wasterlain A Dragoo J Platelet-rich plasma as a treatment for patellar tendinopathy: a double-blind randomized controlled trial. Individual patient data (as supplied June 2013) Data on file · DOI · Paper page
  21. Ferrero, 2012, Ultrasound-guided injection of platelet-rich plasma in chronic Achilles and patellar tendinopathy, Journal of Ultrasound, 15, 260, 10.1016/j.jus.2012.09.006 · DOI
  22. Figueroa, 2010, Magnetic resonance imaging evaluation of the integration and maturation of semitendinosus-gracilis graft in anterior cruciate ligament reconstruction using autologous platelet concentrate, Arthroscopy, 26, 1318, 10.1016/j.arthro.2010.02.010 · DOI · Paper page
  23. Radice, 2010, Comparison of magnetic resonance findings in anterior cruciate ligament grafts with or without autologous platelet-derived growth factors, Arthroscopy, 26, 50, 10.1016/j.arthro.2009.06.030 · DOI · Paper page
  24. Silva, 2009, Anatomic ACL reconstruction: does the platelet-rich plasma accelerate tendon healing?, Knee Surgery, Sports Traumatology, Arthroscopy, 17, 676, 10.1007/s00167-009-0762-8 · DOI · Paper page
  25. Carr A Platelet rich plasma and rotator cuff tendons http://www.controlled-trials.com/ISRCTN10464365/ (accessed 26 August 2013) · doi:10.1186/isrctn10464365
  26. Costa M Achilles tendinopathy management: platelet rich plasma versus eccentric loading programme http://www.controlled-trials.com/ISRCTN95369715/ (accessed 26 August 2013) · doi:10.1186/isrctn95369715
  27. Walters B Effect of intraoperative application of autologous PRP on post operative morbidity in ACL reconstruction using autologous bone patellar tendon bone graft harvest http://clinicaltrials.gov/show/NCT01765712 (accessed 26 August 2013)
  28. Brazier, 1992, Validating the SF-36 health survey questionnaire: new outcome measure for primary care, BMJ, 305, 160, 10.1136/bmj.305.6846.160 · DOI · Paper page
  29. Chahal, 2012, The role of platelet-rich plasma in arthroscopic rotator cuff repair: a systematic review with quantitative synthesis, Arthroscopy, 28, 1718, 10.1016/j.arthro.2012.03.007 · DOI · Paper page
  30. Clayton, 2008, The epidemiology of musculoskeletal tendinous and ligamentous injuries, Injury, 39, 1338, 10.1016/j.injury.2008.06.021 · DOI · Paper page
  31. Long, 2012, Platelet-rich plasma: the PAW classification system, Arthroscopy, 28, 998, 10.1016/j.arthro.2012.04.148 · DOI · Paper page
  32. Vos, 2010, Platelet-rich plasma injection for chronic Achilles tendinopathy, JAMA, 303, 144, 10.1001/jama.2009.1986 · DOI · Paper page
  33. Vos, 2010, Autologous growth factor injections in chronic tendinopathy: a systematic review, British Medial Bulletin, 95, 63, 10.1093/bmb/ldq006 · DOI · Paper page
  34. Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
  35. Dohan Ehrenfest, 2009, Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF), Trends in Biotechnology, 27, 158, 10.1016/j.tibtech.2008.11.009 · DOI · Paper page
  36. 2007, Guide to the preparation, use and quality assurance of blood components
  37. Filardo, 2010, Use of platelet-rich plasma for the treatment of refractory jumper's knee, International Orthopaedics, 34, 909, 10.1007/s00264-009-0845-7 · DOI · Paper page
  38. Foster, 2009, Platelet-rich plasma: from basic science to clinical applications, American Journal of Sports Medicine, 37, 2259, 10.1177/0363546509349921 · DOI · Paper page
  39. Khan, 1999, Histopathology of common tendinopathies. Update and implications for clinical management, Sports Medicine, 27, 393, 10.2165/00007256-199927060-00004 · DOI · Paper page
  40. Kitaoka, 1994, Clinical rating systems for the ankle-hindfoot, midfoot, hallux, and lesser toes, Foot & Ankle International, 15, 349, 10.1177/107110079401500701 · DOI
  41. Kiter, 2006, Comparison of injection modalities in the treatment of plantar heel pain: a randomized controlled trial, Journal of the American Podiatric Medical Association, 96, 293, 10.7547/0960293 · DOI
  42. Kukkonen, 2013, Investigating minimal clinically important difference for Constant score in patients undergoing rotator cuff surgery, Journal of Shoulder and Elbow Surgery, 22, 1650, 10.1016/j.jse.2013.05.002 · DOI · Paper page
  43. Lee, 2011, Musculoskeletal applications of platelet-rich plasma: fad or future?, American Journal of Roentgenology, 196, 628, 10.2214/AJR.10.5975 · DOI
  44. Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
  45. Maffulli, 2003, Types and epidemiology of tendinopathy, Clinical Journal of Sports Medicine, 22, 675, 10.1016/S0278-5919(03)00004-8 · DOI · Paper page
  46. Masthoff, 2005, Validation of the WHO Quality of Life assessment instrument (WHOQOL-100) in a population of Dutch adult psychiatric outpatients, European Psychiatry, 20, 465, 10.1016/j.eurpsy.2004.09.012 · DOI
  47. Paoloni, 2005, The use of therapeutic medications for soft-tissue injuries in sports medicine, Medical Journal of Australia, 183, 384, 10.5694/j.1326-5377.2005.tb07091.x · DOI
  48. Peerbooms, 2010, Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up, American Journal of Sports Medicine, 38, 255, 10.1177/0363546509355445 · DOI · Paper page
  49. Revill, 1976, The reliability of a linear analogue for evaluating pain, Anaesthesia, 31, 1191, 10.1111/j.1365-2044.1976.tb11971.x · DOI · Paper page
  50. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012
  51. Robinson, 2001, The VISA-A questionnaire: a valid and reliable index of the clinical severity of Achilles tendinopathy, British Journal of Sports Medicine, 35, 335, 10.1136/bjsm.35.5.335 · DOI · Paper page
  52. Schepull, 2011, Autologous platelets have no effect on the healing of human achilles tendon ruptures, American Journal of Sports Medicine, 39, 38, 10.1177/0363546510383515 · DOI · Paper page
  53. Sheth, 2012, Efficacy of autologous platelet-rich plasma use for orthopaedic indications: a meta-analysis, Journal of Bone and Joint Surgery -American Volume, 94, 298, 10.2106/JBJS.K.00154 · DOI · Paper page
  54. Sonnleitner, 2000, A simplified technique for producing platelet-rich plasma and platelet concentrate for intraoral bone grafting techniques: A technical note, International Journal of Oral & Maxillofacial Implants, 15, 879
  55. Taylor, 2011, A systematic review of the use of platelet-rich plasma in sports medicine as a new treatment for tendon and ligament injuries, Clinical Journal of Sport Medicine, 21, 344, 10.1097/JSM.0b013e31821d0f65 · DOI · Paper page
  56. Moraes, 2012, Platelet rich therapies for musculoskeletal soft-tissue injuries (Protocol), Cochrane Database of Systematic Reviews, 10.1002/14651858.CD010071 · DOI

Cited by

See all 156

Metadata

Authors
Moraes, V. Y., Lenza, M., Tamaoki, M. J., Faloppa, F., & Belloti, J. C.
Venue
Cochrane Database of Systematic Reviews
Published
2013-12-23
Issue
12
Pages
CD010071-CD010071
ISSN
1361-6137 (ISSN-L)
OpenAlex
W4234532368
Cited by
156
References
3
Type
reference entry
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Platelet-rich therapies for musculoskeletal soft tissue injuries. https://app.cochat.ai/papers/10.1002/14651858.cd010071.pub2
The paper
Moraes, V. Y., Lenza, M., Tamaoki, M. J., Faloppa, F., & Belloti, J. C. (2013). Platelet-rich therapies for musculoskeletal soft tissue injuries. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd010071.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.